Miao Tong-Guo, Zhang Shi-Ya, Zhang Yun-Jing, Ma Dong, Nan Yue-Min
Department of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, Shijiazhuang, 050017, Hebei, People's Republic of China.
School of Public Health, North China University of Science and Technology, Tangshan, 063210, Hebei, People's Republic of China.
Sci Rep. 2024 Sep 16;14(1):21614. doi: 10.1038/s41598-024-72291-5.
Portal vein tumor thrombosis (PVTT) is one of the common complications of HCC and represents a sign of poor prognosis. PVTT signifies advanced liver cancer, deteriorating liver function, and heightened susceptibility to intrahepatic dissemination, systemic metastasis, and complications related to portal hypertension. It is important to seek novel strategies for PVTT arising from HCC. Portal vein tumor thrombus (PVTT) in hepatocellular carcinoma (HCC) represents a worse liver function, less treatment tolerance, and poor prognosis. This study aimed to investigate the diagnostic value of the combination of the DeRitis ratio (AST/ALT) and alkaline phosphatase (ALP) index (briefly named DALP) in predicting the occurrence risk of PVTT in patients with HCC. We performed a retrospective study enrolling consecutive patients with HCC from January 2017 to December 2020 in Hebei Medical University Third Hospital. ROC analysis was performed to estimate the predictive effectiveness and optimal cut-off value of DALP for PVTT occurrence in patients with HCC. Kaplan-Meier analysis revealed the survival probabilities in each subgroup according to the risk classification of DALP value. Univariate and multivariate Logistics regression analyses were applied to determine the independent risk for poor prognosis. ROC analysis revealed that the optimal cut-off value for DALP was 1.045, with an area under the curve (AUC) of 0.793 (95% CI 0.697-0.888). Based on the DALP classification (three scores: 0-2) with distinguishable prognoses, patients in the score 0 group had the best prognosis with a 1-year overall survival (OS) of 100%, whereas score 2 patients had the worst prognosis with 1-year OS of 72.4%. Similarly, there was a statistically different recurrence-free survival among the three groups. Besides, this risk classification was also associated with PVTT progression in HCC patients (odds ratio [OR] 5.822, P < 0.0001). Pathologically, patients in the score 2 group had more advanced tumors considering PVTT, extrahepatic metastasis, and ascites than those in score 0, 1 groups. Moreover, patients with a score of 2 had more severe hepatic inflammation than other groups. Combination of DeRitis ratio and ALP index presented a better predictive value for PVTT occurrence in patients with HCC, contributing to the tertiary prevention.
门静脉癌栓(PVTT)是肝癌常见的并发症之一,也是预后不良的标志。PVTT意味着肝癌进展、肝功能恶化,以及肝内播散、全身转移和门静脉高压相关并发症的易感性增加。寻找针对肝癌所致PVTT的新策略很重要。肝细胞癌(HCC)中的门静脉癌栓(PVTT)意味着肝功能更差、治疗耐受性更低和预后不良。本研究旨在探讨DeRitis比值(AST/ALT)与碱性磷酸酶(ALP)指数联合(简称为DALP)在预测HCC患者PVTT发生风险中的诊断价值。我们进行了一项回顾性研究,纳入了2017年1月至2020年12月在河北医科大学第三医院连续就诊的HCC患者。进行ROC分析以评估DALP对HCC患者PVTT发生的预测有效性和最佳截断值。Kaplan-Meier分析根据DALP值的风险分类揭示了各亚组的生存概率。应用单因素和多因素Logistic回归分析确定预后不良的独立危险因素。ROC分析显示,DALP的最佳截断值为1.045,曲线下面积(AUC)为0.793(95%CI 0.697 - 0.888)。基于具有可区分预后的DALP分类(三个评分:0 - 2),评分0组患者预后最佳,1年总生存率(OS)为100%,而评分2组患者预后最差,1年OS为72.4%。同样,三组之间的无复发生存率存在统计学差异。此外,这种风险分类也与HCC患者的PVTT进展相关(比值比[OR] 5.822,P < 0.0001)。病理上,与评分0、1组相比,评分2组患者在PVTT、肝外转移和腹水方面肿瘤进展更明显。此外,评分2的患者肝脏炎症比其他组更严重。DeRitis比值与ALP指数联合对HCC患者PVTT的发生具有更好的预测价值,有助于三级预防。